Literature DB >> 21562707

The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer.

Malgorzata Banys1, Natalia Krawczyk, Sven Becker, Jolanta Jakubowska, Annette Staebler, Diethelm Wallwiener, Tanja Fehm, Ralf Rothmund.   

Abstract

Recent studies have shown that the detection of circulating tumor cells (CTC) pre and postoperatively in the peripheral blood of primary breast cancer patients may be an indicator for poor survival. This study aimed to investigate the influence of removal of the primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. 209 primary breast cancer patients could be included into this analysis. Blood sampling was performed both pre and postoperatively. The blood specimens were immunomagnetically enriched using AdnaTest BreastCancerSelect within 4 h after blood withdrawal, followed by RNA isolation and subsequent gene expression analysis by reverse transcription and multiplex PCR using AdnaTest BreastCancerDetect. Three breast cancer-associated tumor markers and two hormone receptor genes were amplified: GA733-2, Muc-1, Her-2, ER, PR. In addition, bone marrow (BM) status was intraoperatively determined. Forty-three of 209 patients (21%) had pre and/or postoperatively circulating tumor cells. The positivity rates after surgery were higher but did not differ significantly (12% pre and 16% postoperatively, P = 0.264). Disseminated tumor cells in BM were seen in 32 of 209 cases (15%). Patients with positive BM status had significantly higher CTC positivity rates both pre and postoperatively compared to those with negative BM status. The most common CTC phenotype was triple negative (24 patients) followed by HER2+/ER-/PR- subtype (10) and ER and/or PR positive (9). Interestingly, 41 of 43 primary tumors (95%) were ER and PR positive. Removal of the primary tumor did not alter the phenotype of CTC. Surgery does not significantly influence the tumor cell load in the blood stream. CTC phenotype before and after the surgery generally remains identical but may differ from that of the primary tumor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562707     DOI: 10.1007/s10549-011-1569-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  21 in total

Review 1.  Circulating tumour cells and cell-free DNA as tools for managing breast cancer.

Authors:  Leticia De Mattos-Arruda; Javier Cortes; Libero Santarpia; Ana Vivancos; Josep Tabernero; Jorge S Reis-Filho; Joan Seoane
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

Review 2.  Circulating Tumor Cells in Early-Stage Breast Cancer.

Authors:  A D Hartkopf; M Banys; N Krawczyk; M Wallwiener; H Schneck; H Neubauer; T Fehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2011-12       Impact factor: 2.915

3.  A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier.

Authors:  Chris E Adkins; Mohamed I Nounou; Rajendar K Mittapalli; Tori B Terrell-Hall; Afroz S Mohammad; Rajaganapathi Jagannathan; Paul R Lockman
Journal:  Cancer Prev Res (Phila)       Date:  2014-10-27

Review 4.  Rebuilding cancer metastasis in the mouse.

Authors:  Meera Saxena; Gerhard Christofori
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

Review 5.  Dormancy in breast cancer.

Authors:  Malgorzata Banys; Andreas D Hartkopf; Natalia Krawczyk; Tatjana Kaiser; Franziska Meier-Stiegen; Tanja Fehm; Hans Neubauer
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-12-05

Review 6.  Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis.

Authors:  Q Lv; L Gong; T Zhang; J Ye; L Chai; C Ni; Y Mao
Journal:  Clin Transl Oncol       Date:  2015-08-11       Impact factor: 3.405

Review 7.  Dissemination from a Solid Tumor: Examining the Multiple Parallel Pathways.

Authors:  Moriah E Katt; Andrew D Wong; Peter C Searson
Journal:  Trends Cancer       Date:  2018-01-10

8.  Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis.

Authors:  Guislaine Barrière; Alain Riouallon; Joël Renaudie; Michel Tartary; Michel Rigaud
Journal:  BMC Cancer       Date:  2012-03-23       Impact factor: 4.430

9.  Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Anna Jakabova; Zuzana Bielcikova; Eliska Pospisilova; Lubos Petruzelka; Piotr Blasiak; Vladimir Bobek; Katarina Kolostova
Journal:  Ther Adv Med Oncol       Date:  2021-07-13       Impact factor: 8.168

10.  Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient.

Authors:  Tania Rossi; Michela Palleschi; Davide Angeli; Michela Tebaldi; Giovanni Martinelli; Ivan Vannini; Maurizio Puccetti; Francesco Limarzi; Roberta Maltoni; Giulia Gallerani; Francesco Fabbri
Journal:  Front Med (Lausanne)       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.